CoreSite Realty Corp. COR 深 滬
等待開盤 11-26 09:30:00 美东时间
374.75
+2.530
+0.68%
華盛通- 最 高377.54
- 今 開374.01
- 成交量 156.39万股
- 最 低 372.65
- 昨 收 372.22
- 總市值 727.02亿
- 52周最高 377.54
- 市盈率 靜 47.08
- 換手率 0.81%
- 52周最低 221.67
- 委 比 0.00%
- 總股本 1.94亿
- 歷史最高 377.54
- 量 比 0.91
- 振 幅 1.31%
- 歷史最低 -7.425
- 每 手 1
- 風險率 33.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
AllianceBernstein Adds 2 Bond ETFs To Meet Rising Demand For Safer, Flexible Income
AllianceBernstein has launched two new bond ETFs, giving investors fresh options for tax-efficient income and core fixed income exposure.
11-12 04:17
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Mizuho Maintains Outperform on Cencora, Raises Price Target to $380
Mizuho analyst Steven Valiquette maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $340 to $380.
11-06 20:59
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.
11-06 02:23
Cencora Sees FY2026 Adj EPS $17.45-$17.75 vs $15.94 Est; Sees Sales $337.365B-$343.791B vs $321.030B Est
Fiscal Year 2026 Expectations on an Adjusted (non-GAAP) Basis 2026 GuidanceFiscal 2025 ActualsRevenue5% to 7% growth$321.3BU.S. Healthcare Solutions Segment(1)5% to 7% growth$285.0BInternational Healthcare Solutions
11-05 19:33
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
